论文部分内容阅读
目的:观察阿瑞匹坦联合托烷司琼、地塞米松预防含顺铂化疗方案引起呕吐的疗效及不良反应。方法 :将76例使用含顺铂化疗方案的肺癌病人随机分为2组,对照组38例化疗过程中使用托烷司琼、地塞米松预防性止呕,观察组38例化疗过程中使用阿瑞匹坦联合托烷司琼、地塞米松预防性止呕。观察比较两组患者用药后急性期呕吐、延迟期呕吐的有效控制率及不良反应发生率。结果 :观察组化疗引起的急性期呕吐及延迟期呕吐的有效控制率高于对照组。两组间不良反应比较无统计学意义。结论 :阿瑞匹坦联合托烷司琼、地塞米松能有效预防含顺铂化疗方案引起的急性期及延迟期呕吐,不良反应可耐受。
Objective: To observe the efficacy and side effects of aprepitant combined with tropisetron and dexamethasone in preventing vomiting induced by cisplatin-containing chemotherapy. Methods: A total of 76 patients with lung cancer who received cisplatin-based chemotherapy were randomly divided into two groups. 38 patients in the control group received tropisetron and dexamethasone prophylaxis and the 38 patients in the observation group were treated with chemotherapy Retapitazine combined tropisetron, dexamethasone prophylactic antiemetic. Observe and compare two groups of patients after treatment of acute vomiting, delayed vomiting, the effective rate of control and adverse reactions. Results: The effective rate of the control group in the observation group induced by acute chemotherapy of vomiting and delayed vomiting was higher than that of the control group. Adverse reactions between the two groups were not statistically significant. Conclusion: Aprepitant combined with tropisetron and dexamethasone can effectively prevent the acute and delayed vomiting caused by cisplatin-containing chemotherapy regimens, and the adverse reactions are tolerable.